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Abstract 
Objective: To compare the impact of various pharmacy-based services on medication adherence and clinical outcomes.  
Design: Prospective, randomized control trial 
Setting: A local endocrinology group (clinic setting) and community pharmacies belonging to a regional integrated delivery network 
(IDN) in Toledo, OH 
Population: Subjects included within this study had type 2 diabetes, were prescribed a minimum of five medications, at least 18 years 
of age, having the ability to self-administer medications as prescribed, and be able to speak and understand English. Subjects were 
required to have Paramount health insurance, must be willing and able to provide informed consent, actively participate in the assigned 
MTM sessions, and have adequate transportation to attend the sessions at a participating pharmacy.   
Methods: Patients were recruited through flyers at practice sites, referrals from physicians and pharmacists, and direct mailers. 
Members of the research team would screen patients to assess their eligibility to participate in the study. Patients who fit the inclusion 
criteria were randomized into one of the following four different groups: Pill Bottle (PB), Blister Pack (BP), Pill Bottle + Medication 
Therapy Management (PB+MTM), and Adherence Pharmacy (BP+MTM). Patients enrolled in the BP groups had their medications 
synchronized. Patients in the AP group were given the option to have their medications delivered, if needed.  
Practice innovation: We partnered with a regional integrated delivery network (IDN) with multiple community pharmacy practice sites 
and a practice group of endocrinologists. A new practice model called Adherence Pharmacy was conceptualized and implemented 
within the community setting and was accessible to patients. 
Main Outcomes Measures: Medication adherence, measured using proportions of days covered (PDC) and pill count scores at baseline, 
3 months, 6 months, 9 months, and 12 months; Hemoglobin A1c (HbA1c), body mass index (BMI), systolic blood pressure (SBP), and 
diastolic blood pressures (DBP) were collected at baseline, 6 months, and 12 months 
Results: A mixed-model ANOVA was used to study the impact of these services on medication adherence, using PDC and pill count 
scores. Results of the 61 patients in the study revealed that there was a statistically significant difference between the PB and BP groups 
(p=0.008); between the PB and BP+MTM groups (p=0.023); and between the PB+MTM and the BP+MTM groups (p=0.041). Except at 
baseline, adherence scores at all time points (0, 3, 6, 9, and 12 months) were significant with the patients in the BP and BP+MTM 
groups having higher adherence compared to those in the PB and PB+MTM groups. Pill count scores had similar results to the PDC 
measures. Insert data from HBA1c, BMI, SBP and DBP. Clinical outcomes were also analyzed using the mixed between-within ANOVA 
and were measured at baseline, 6, and 12 months. Patients in the MTM groups reached the American Diabetes Association goal of 7%, 
whereas the patients in the PB group did not reach a goal at 12 months. All groups, except for the PB only group, indicated a statistically 
significant change from baseline to 12 months. When comparing body mass index (BMI) scores across groups over time, patients in the 
BP+MTM group showed the lowest BMI at 12 months. There were not any significant differences across the groups, but patients in the 
two MTM groups saw greater improvement in their BMI scores than patients in the other two groups. There were no significant 
differences between groups in SBP and DBP reduction. However, patients in the two BP groups reached a SBP goal sooner (per the 
Eighth Joint National Committee) than patients in the PB+MTM and PB groups.  
Conclusion: Patients had improved clinical outcomes and adherence rates when using blister packaging and medication therapy 
management services, individually and in combination. Blister packaging seemed to have a greater impact on medication adherence 
while MTM services helped improve clinical endpoints. However, patients who received the combination of services offered within the 
AP demonstrated higher improved clinical outcomes and adherence rates when compared to patients who did not. While each of these 
services was found to be more impactful that dispensing medications in pill bottles, combining them can provide a greater benefit to 
patients.  
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Introduction 
Nearly 133 million Americans have at least one chronic health 
condition and take multiple medications.1 Approximately 
three in four adults in the United States (U.S.) are non-
adherent to their medications and about 50% of patients who 
have a chronic health condition do not take their medications 
as prescribed.2-5 Specifically, the adherence rates for patients 
with type 2 diabetes ranges from about 36% to 93%.6 
Medication non-adherence is defined as a patient’s failure to 
follow a prescribed therapeutic regimen.7 Several studies have 
shown that medication non-adherence is linked to increased 
morbidity and mortality rates.8, 9 Because medication non-
adherence is a multi-faceted problem, it requires a multi-
faceted solution. 
 
In order to resolve the issue of medication non-adherence, it 
is important to understand the factors affecting a patient’s 
medication-taking behavior. Some of these barriers to 
medication adherence include forgetting to take their 
medications, not picking up new prescriptions or refills, not 
taking medications because of the side effects, costs, 
transportation issues, lack of understanding, complex 
medication regimens, and poor health literacy.2, 3 On average, 
adults in the U.S. take four prescription medications daily.10 
Patients who are taking multiple medications are at a higher 
risk of falling victim to medication non-adherence.11 There are 
various strategies that can help improve medication non-
adherence, including but not limited to, telephone refill 
reminders, pill boxes, alarms, education programs, and mobile 
application aids.12, 13 While each of these methods can help 
improve medication-taking behavior and medication 
adherence, they are often either inaccessible to patients or are 
seldom brought to the patient’s attention. Patients in the U.S. 
make nearly four medical visits to their physicians annually and 
most physician visits average about 15 minutes.14, 15 This does 
not afford doctors an opportunity to effectively engage with 
their patients in a discussion about their medication-taking 
behaviors or to identify barriers that prevent them from 
becoming non-adherent. On the contrary, a patient visits their 
pharmacy at least once a month and, very often, multiple 
times if they are on multiple chronic medications.16 
Pharmacies have the ability to offer a large variety of services 
that can help address the barriers impacting a patient’s 
medication-taking behavior based on their individual 
characteristics.  
 
Most community pharmacies dispense medications in pill 
bottles. However, other forms of dispensing medications have 
existed for years, although they have predominantly been 
used in non-community pharmacy settings, such as long-term 
care. Adherence packaging, or blister packaging (BP), is a tool 
that provides a visual aid to indicate the day and/or time 
medications should be administered. Dispensing medications 
in blister packaging rather than pill bottles has been shown to 
improve adherence and clinical outcomes.18-20 This can replace 
pill boxes that patients or caregivers typically fill after receiving 
their prescriptions in pill bottles.17 To reduce multiple trips to 
the pharmacy, pharmacies are able to synchronize patients’ 
medications to be filled on one day. This program is called 
medication synchronization, or med sync. Med sync is carried 
out by pharmacy staff members who work with both the 
patients and their insurance companies to fill their 
prescriptions. Because blister packs are filled monthly, 
patients who receive them will usually have their medications 
synchronized. However, this service is also made available for 
patients who receive prescriptions in pill bottles alone. 
Pharmacies who provide med sync have seen an increase in 
patient satisfaction rates, refills, and return on investment.21, 
22 Another service that provides convenience to patients is the 
availability to opt-in for delivery of prescriptions. Patients who 
lead busy lives or who are unable to leave their homes, due to 
lack of transportation means or because they are home-
bound, are unable to receive their medications on time, if at 
all. Pharmacies can assist patients in overcoming these barriers 
by providing patients a delivery service option. This ensures 
that patients are able to receive their prescriptions on time. 
One setback to this service, however, is that patients may not 
be prompted to speak with a pharmacist, even when a 
consultation note is attached to the bag. For patients who are 
able to come to the pharmacy, they are able to learn more 
about their prescriptions. Pharmacists have the advantage of 
being one of the most accessible healthcare professionals and 
are able to spend more time educating patients on their 
medications in comparison to other healthcare providers.23, 24 
Medication therapy management (MTM) services are 
provided by pharmacists to help patients understand their 
disease state(s) and medications to optimize therapeutic 
outcomes.25 These services can be provided to patients face-
to-face or telephonically. Several studies have demonstrated 
that MTM interventions lead to improved clinical outcomes for 
patients.26, 27 One study exists that shows that the combination 
of blister packaging with MTM significantly improves 
adherence and decreases in hospitalizations; however, it did 
not determine effects on clinical outcomes and was a 
retrospective study on a specific population of Medicaid 
patients.28 While each of these interventions (blister 
packaging, med sync, delivery services, and MTM) have shown 
efficacy in improving adherence rates and clinical outcomes 
individually, there is a still a need for evaluating the effects of 
these outcomes when combining these services.  
 
As the role of the pharmacist evolves and continues to expand, 
pharmacies are becoming better equipped with resources and 
are starting to offer some of these services. Since the birth of 
Medicare Prescription Drug, Improvement, and Modernization 
Act of 2003, MTM services have become an increasingly 
popular service provided at community pharmacies.29 
Implementing MTM services within the pharmacy workflow 
requires a paradigm shift in the pharmacy practice model. A 
traditional pharmacy workflow model involves patients 
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dropping off a prescription, pharmacy technicians counting 
pills on a tray and placing them in a pill bottle, and pharmacists 
verifying the prescription.26 Pharmacies are in need of a model 
that incorporates important elements that can optimize 
patient outcomes. The adherence pharmacy (AP) is an 
innovative pharmacy practice model that combines use of 
blister packaging, medication synchronization, MTM services, 
and the availability of delivery services. These services are 
offered to patients in a community pharmacy setting. The goal 
of this study was to compare the impact of various pharmacy-
based services on medication adherence and clinical 
outcomes.  
 
Objective 
The objectives of this study were to: 1. examine the effect of 
an Adherence Pharmacy (AP) practice model on medication 
adherence when compared to other community pharmacy 
models for patients with type 2 diabetes; 2. examine the 
impact of the AP model services on clinical health outcomes 
when compared to other community pharmacy models for 
patients with type 2 diabetes.  
 
Methods 
Study Design and Study Population  
This study used a prospective, randomized control trial design 
that began in 2014. Researchers partnered with a regional 
integrated delivery network (IDN) with multiple pharmacy 
sites and a group of endocrinologists. Patients were recruited 
through flyers at the practice sites, referrals from physicians 
and pharmacists, and direct mailers. They were provided with 
a number to call to express their interest in the study. 
Members of the research team would screen these patients to 
assess the eligibility to participate in the study. Patients were 
enrolled if they met the following criteria: they were able to 
speak and understand English, 18 years of age or older, 
diagnosed with type 2 diabetes, and/or hypertension, 
hyperlipidemia, were currently prescribed a minimum of five 
medications, could self-administer their medications as 
prescribed by their doctor, were willing to fill prescriptions at 
a participating pharmacy, had adequate transportation to 
attend counseling sessions at a participating pharmacy, were 
willing to have lab work done as requested and have results 
delivered by themselves or have the physician fax them to the 
participating pharmacy, have a connected, in-service phone 
number to be reached at for telephonic reminders and follow-
ups, have Paramount health insurance, and were willing to 
provide informed consent to participate in the study. They 
were excluded if they had type 1 diabetes, were diagnosed 
with a terminal illness and given less than three years to live, 
pregnant/expected to become pregnant, were planning to 
leave the area or employer in the next three years, and were 
currently enrolled in another MTM study. Patients who met 
the inclusion criteria were randomized into one of the 
following four groups: Pill Bottle (PB), Blister Pack (BP), Pill 
Bottle + Medication Therapy Management (PB+MTM), and 
Adherence Pharmacy (AP)(BP+MTM). Patients enrolled in the 
BP groups had their medications synchronized. Patients in the 
AP group were given the option to have their medications 
delivered, if needed. The research team used a covariate 
adaptive randomization process to divide subjects into four 
equally distributed groups. This randomization strategy 
allowed a new subject to sequentially be assigned to a 
particular group by taking into account the specific 
covariates/confounding variables and previous assignments of 
subjects. This strategy used the method of minimization to 
assess the imbalance of sample size among several covariates. 
Our CONSORT flow diagram shows the phases of how patients 
were randomized and allocated into the four groups. 
 
Setting for MTM Services 
Participants received MTM services from clinical pharmacists 
at one of the participating pharmacy practice sites. There were 
a total of 6 pharmacists involved in the study, of which 2 
pharmacists conducted the MTM services. These two 
American Pharmacists Association (APhA) MTM-certified 
pharmacists were trained on the protocol for the study, 
expectations/roles of MTM, and have previously provided 
MTM services to patients. There were 5 pharmacy practice 
sites available and enrolled patients were able to choose which 
one of the participating pharmacy locations to fill their 
medications based on their personal preference(s). Subjects in 
the non-MTM groups did not receive additional services from 
the pharmacists beyond standard counseling, if they opted to 
be counseled. Standard counseling included information about 
what the drug was used for and any special instructions that 
the subject should have been made aware of while on the 
medication. This occurred when the medication was picked up.  
 
Follow-up Visits 
There were two types of follow-up visits: telephonic and face-
to-face. Follow-up visits were conducted over the telephone 
by a research assistant (RA) at 3, and 9 months to assess 
adherence, whereas visits at 6 and 12 months were conducted 
face-to-face with the pharmacist for the MTM group or with a 
member of the research team for the the non-MTM groups. 
Ten days prior to each interaction (baseline visits, telephonic 
follow-ups, etc.) subjects received a reminder phone call. 
Adherence information was collected via medical and 
prescription claims data and via pill counts. Follow-up clinical 
information was extracted from the patients electronic charts 
or collected by the RA when the patient returned to the 
pharmacy for their 6- and 12-month visits. The telephonic 
follow-ups consisted of a self-pill count. The purpose of the 
face-to-face follow-ups for participants who were randomized 
in the MTM groups (PB+MTM and BP+MTM) was to counsel 
them on their medication regimen, disease states, and address 
any problems or concerns subjects had, create a Patient 
Medication Record, discuss a Medication Action Plan etc. 
During the follow-up visits the patients’ medication action 
plans (MAP) were reassessed and goals were adjusted.  
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Outcome Measures  
The primary outcome measures for this paper were 
medication adherence and clinical outcomes. The authors are 
currently working on a second paper describing the findings 
from the humanistic and economic outcomes of the study. 
Medication adherence was measured by proportion of days 
covered (PDC) and pill count scores. Researchers used 
prescription claims data to measure the participants’ 
adherence to medications and to then calculate the PDC. 
Patients were also trained on how to perform self-pill counts 
at their initial enrollment visit. During the telephonic follow-up 
visits at 3 and 9 months, the participants were asked by the 
research assistant to perform the pill counts while on the 
phone and to provide the researcher with the information. To 
validate the self-reported telephonic pill count, patients were 
asked to bring their unused pill bottles and blister packs to the 
pharmacy at their 6 and 12 month visit and the RAs performed 
pill counts.  
  
Clinical outcomes that were measured were hemoglobin A1c 
(HbA1c), body mass index (BMI) [height and weight were 
measured to calculate BMI], systolic blood pressure (SBP), and 
diastolic blood pressure (DBP). Blood pressure recordings were 
measured at the physician’s office by physician office 
personnel and we were able to access their measurements 
from their electronic medical record. 
 
Data Analysis 
Subject baseline characteristics are listed in Table 1. These 
comparisons were presented in order to identify any major 
baseline therapy differences that could potentially affect the 
results. For all statistical tests, a significance level of 0.05 was 
used. Post hoc comparisons used the Tukey HSD test or paired 
sample t-tests to investigate within-group differences. All 
pairwise comparisons were adjusted with Bonferroni 
corrections and were assumed to be significant at alpha level 
0.05 or 0.0125. All data was assessed prior to final analysis to 
check for violations to assumptions. 
  
Adherence was measured as a continuous variable ranging 
from 0 to 1. A mixed model analysis of variance (ANOVA) was 
used to compare adherence rates between and within the four 
different groups. Adherence was a categorical variable divided 
into three levels based on the participants’ PDC score: high 1-
0.8, intermediate 0.79-0.6, and low adherence <0.6. Clinical 
outcomes were analyzed using the mixed between-within 
ANOVA.  
 
Results  
Baseline Characteristics 
Table 1 shows that there were no statistical significant 
differences across groups at baseline. In addition to 
demographics, we analyzed their baseline values of average 
number of medications, BMI, and Hba1c.  
 
Medication Adherence  
Medication adherence (Table 2) was most improved in the 
groups with BP. Of all the groups, patients enrolled in the 
BP+MTM group, or the AP group, showed the highest PDC 
score at 12 months. When measuring the PDC, the interaction 
between time of measurement and groups was significant with 
a large effect size (Wilks Lambda=0.57, F(3,57)=7.13, p=0.004, 
partial eta squared=0.64). There was also a significant main 
effect for time (Wilks Lambda=0.64, F(4,57)=8.12, p=0.013, 
partial eta squared=0.22). Additionally, the main effect 
comparing the four groups was significant with a large effect 
size (F(3,57)=11.7, p<0.01, partial eta squared=0.53), 
suggesting a considerable difference in the effectiveness of the 
groups. Post-hoc comparisons using the Tukey HSD test 
indicated significant differences in PDC between the PB and BP 
groups (p=0.008), with patients in the BP group having 
significantly better adherence scores than patients in the PB 
group. Additionally, significance was seen between PB and 
BP+MTM (p=0.023) and the PB+MTM and the BP+MTM 
(p=0.041) groups. Except at baseline, adherence scores at all 
time points were significant with patients in the BP and the 
BP+MTM groups having higher adherence compared to those 
in the PB and the PB+MTM groups. Even though patients in the 
PB+MTM group had improved adherence at 3 months, they 
weren’t able to sustain or improve their adherence at the 6-
month time point, unlike patients in the two BP groups. 
However, after speaking with the pharmacist at the 6-month 
time-points patients who were in the PB+MTM group were 
able to significantly improve their adherence scores. 
When measuring pill count scores (Table 3), the interaction 
between time of measurement and the groups was significant 
with a large effect size (Wilks Lambda=0.426, F(3,57)=12.32, 
p=0.00, partial eta squared=0.43). Similar to the PDC results, 
the BP+MTM group, or the AP group, showed the highest pill 
count score at 12 months. Patients with scores <0.60, 0.60-
0.79, and 0.80-1 were deemed to have low adherence, 
intermediate adherence, and high adherence, respectively. 
Results indicated a significant main effect for time (Wilks 
Lambda=0.69, F(4,57)=5.862, p<0.001) with a large effect size 
size (partial eta squared=0.30). Additionally, the main effect 
comparing the four groups was significant with a large effect 
size (Wilks Lambda=0.251, F(3,57)=8.61, p=0.006, partial eta 
squared=0.38), suggesting a considerable difference in the 
effectiveness of the groups. Post-hoc comparisons using the 
Tukey HSD test indicated significant differences in adherence 
between PB and BP groups (p=0.005), with patients in the BP 
group having significantly better adherence scores than 
patients in the PB group. Additionally, significant differences 
were observed between PB and BP+MTM (p=0.002), and again 
patients in the PB group had significantly lower adherence 
scores than patients in the BP+MTM group. No other 
significant differences in mean pill count scores were observed 
among the other groups. Post-hoc comparisons for various 
time points indicated significant difference in adherence 
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between the PB+MTM and the BP group at 6 months 
(p=0.012), between the BP+MTM and PB+MTM at the 12-
months (p=0.031), and between PB+MTM and the PB group at 
the 12- month (p=0.001) time point. Additionally, significant 
differences were observed at the p< 0.05 level, between 
BP+MTM group and the PB group, and the BP and PB group at 
6, 9 and 12 months.  
Clinical Outcomes  
In all measures for clinical outcomes, the BP+MTM group had 
the most favorable results. For HbA1c (Table 4), patients who 
were in the BP+MTM group, or the AP group, had the lowest 
average HbA1c values at the end of the year when compared 
to the other groups. The interaction between the groups and 
time was significant (Wilks Lambda=0.79, F(3,56)=5.03, partial 
eta squared=0.21, p=0.002) and there was a substantial main 
effect for time (Wilks Lambda=0.8815, F(2,56)=5.67, partial eta 
squared=0.67, p=0.001), with patients in the two MTM groups 
improving the most over time, followed by patients in the BP 
only group. The main effect for groups was also significant 
(Wilks Lambda=0.37, F(2,56)=21.7, partial eta squared=0.74, 
p=0.000). Post hoc comparisons indicated significant 
differences between the two MTM groups and the PB group. 
There were statistically significant changes from baseline to 6 
months and from baseline to 12 months in both MTM groups. 
All groups except for the PB group had significant changes from 
baseline to 12 months. Also, patients in the MTM groups 
reached the ADA goal of 7% and dropped by almost 2% points, 
while patients in the BP group got close to this goal at the 12-
month time point and dropped by 1.4% points. Patients in PB 
did not reach goal at 12 months.  
Results from the analysis of BMI scores (Table 5) indicated a 
significant main effect for time (Wilks Lambda=0.847, 
F(2,48)=4.319, p=0.019) and a large effect size (partial eta 
squared=0.153). Although there weren’t any significant 
differences across groups, 11 patients in the two MTM groups 
saw greater improvement in their BMI scores than patients in 
the other 2 groups. scores for patients receiving the BP 
continuously improved over the course of the year, although 
this decrease was more gradual than patients in the MTM 
groups. The lowest average BMI score was seen in the 
BP+MTM group, or the AP group. 
Per the Eighth Joint National Committee (JNC 8), the goal for 
SBP/DBP is <140/90 mmHg for patients 18 to 59 years of age 
without major comorbidities and for patients 60 years or older 
who have diabetes, CKD, or both.28 According to this guideline, 
most patients in this study were at goal at baseline. No 
statistically significant differences were detected between 
time and group variables for SBP (Table 6). However, at the 
end of 12 months, the mean SBP of 119.93 mmHg for patients 
who had packaging and MTM was lower than the mean SBP of 
all other groups. At 12 months, the patients in the BP+MTM 
group, or the AP group, showed the lowest average SBP. There 
was no significant main effect comparing the four groups, 
suggesting no statistical difference in the effectiveness of the 
interventions for SBP. A sub-group analysis was performed on 
a small group of patients (n=17) who weren’t at goal at 
baseline. While these numbers were too small to indicate 
statistical significance, it must be noted that most patients in 
the two BP groups reached goal sooner than patients in the 
PB+MTM and PB groups.  
Diastolic blood pressure (DBP) (Table 7) results showed a 
significant main effect for time (Wilks Lambda=0.859, 
F(2,48)=3.927, p=0.026) and a large effect size (partial eta 
squared = 0.141). There were no significant differences 
between groups and no significant interaction effects. All 
groups showed a reduction in DBP across the three time 
periods. Sub-group analysis for patients who weren’t at goal at 
baseline, found a higher number of patients in the BP groups 
reached goal at 6 months when compared to patients in the 
other groups. Although, this finding wasn’t significant, it did 
suggest the impact of blister packs and medication 
synchronization on improving blood pressure.  
 
Discussion 
The adherence pharmacy (AP) practice model can play a large 
role in effectively improving patient outcomes. Findings from 
this study support the use of adherence packaging, or blister 
packaging (BP), in improving medication adherence, and the 
use of MTM services provided by pharmacists. Patients who 
were in the BP+MTM group saw the most significant 
improvements both in their adherence rates and clinical 
outcomes. All patients in the BP groups progressed from low 
to intermediate adherence to high adherence within the first 
3 months of being on adherence packs. One possible reason 
for this is that blister packs provide a visual aid for patients 
who may struggle to remember to take their medications.18-20 
Additionally, they continued to see a gradual improvement in 
their proportion of days covered (PDC) scores, such that the 
average PDC score for this group was 0.90 at 12 months. 
Patients who were receiving MTM services saw improvements 
in their clinical outcomes in comparison to the patients in the 
pill bottle (PB) only group. The goal of MTMs is to identify 
medication-related problems, to empower the patient in 
understanding his or her medications and disease state(s), and 
to develop a medication action plan for them to address any 
medication-related issues.25 As a result of these services, 
patients were able to achieve significantly improved clinical 
outcomes. By combining the blister packaging with MTMs, 
patients were able to see both improved adherence rates and 
clinical outcomes.  
Blister packs have been used in long-term care settings for the 
past several decades.32 They are only recently being adopted 
in community pharmacies. Concerns and perceived barriers to 
implementing blister packaging services into the pharmacy 
workflow such as the time spent to manually package patients’ 
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medications, the size of the machines, and the inability to load 
a large number of medications have prevented pharmacies 
from offering blister packaging.33  While not always, packaging 
is often done by synchronizing patients’ medications, thereby 
eliminating the need for multiple trips to the pharmacy, and/or 
creating multiple blister packs on a monthly basis. Pharmacies 
have also expressed their concern for lack of software that can 
help them efficiently synchronize the patients’ medications, 
thereby adding more time to the dispensing process and 
hindering workflow in the pharmacy. However, with advances 
in automation and technology, both these barriers have now 
been overcome. Machines that package the patients’ 
medications are now much smaller in size, have a greater 
output, can store and package more medications, and are 
reasonably priced. There are now multiple software programs 
that can help with refill synchronization and a number of them 
can be interfaced with existing pharmacy systems.34 
Integrating this technology in the community pharmacy allows 
patients to have their medications synchronized to be filled on 
one day each month and filled in blister packaging to improve 
their adherence rates.  
 
In this study, both the BP groups and MTM groups had positive 
outcomes. Investing in either of these services will help a 
pharmacy offer a better means of improving patient 
outcomes. However, it is important to note that both of these 
services improve outcomes by targeting separate primary 
markers. BPs improve medication adherence, while MTM 
helps ensure a patient is receiving the most effective 
treatment option that can help control their disease. Both 
adherence and clinical outcomes are important markers in 
patient care. Therefore, in order to see the greatest 
improvement in patient outcomes, pharmacies would benefit 
from combining these services. As seen in this study, patients 
who were in the BP+MTM group received all services offered 
by the adherence pharmacy (AP) model. This group, by far, had 
the greatest impact on patient adherence rates and clinical 
outcomes. Zillich et al produced similar results as ours when 
evaluating a program that combined MTM with adherence 
packaging in terms of improvements in adherence. 28 As 
pharmacies and providers seek to find better ways of targeting 
medication non-adherence, Adherence Pharmacy seems to 
provide a possible solution to addressing the non-adherence 
problem. 
 
Limitations 
One major limitation to our study was that the sample size was 
relatively small, which might suggest a low external validity. 
Additionally, participants were those who were able to speak 
and understand English, which removed the barrier 
pharmacists may face when attempting to provide MTM 
services to non-English speaking patients. Although there were 
only two pharmacists with similar experience and certification 
providing MTM services, the quality of their services was not 
assessed and may have varied. We also did not assess whether 
there were differences in the outcomes at the different 
pharmacies. Although adherence was measured through pill 
counts and prescription claims data, we could not know for 
certain if the participant actually took their medications. There 
may have been a few medication changes that were not 
assessed during the course of the study. Another limitation for 
adherence results was that patients in the PB group had the 
lowest PDC value at baseline in comparison to the other 
groups. This may have presented some unfavorable bias to 
that group in that patients may have remained non-adherent 
throughout the study. However, this bias was unavoidable 
since the patients were randomized into this group. A 
limitation in the clinical outcomes, specifically the blood 
pressure changes, was that only a small group of patients 
(n=17) were not at the JNC 8 recommended blood pressure 
goal at baseline. Future studies should focus on larger sample 
sizes and testing these results in multiple regions of the 
country. 
 
Conclusion 
This study provides a better understanding of the impact that 
pharmacists and pharmacy-based services, such as blister 
packs, medication synchronization, MTMs, and delivery can 
have on patient outcomes. While adherence pharmacy would 
be an ideal option, starting out with either a MTM program or 
a blister packaging service can provide pharmacies and their 
patrons a much better alternative to improving their health 
than the current practice of simply dispensing medications in 
pill bottles. With the move toward provider status and 
pharmacies being held accountable for performance metrics 
and star ratings, we can no longer rely on a method of 
dispensing that has worked in the past. Pill bottles have limited 
impact on improving outcomes of patients with multiple 
chronic conditions. Based on the findings of this study a key 
recommendation for pharmacies would be to diversify their 
service portfolio and provide patients with service options that 
can truly help improve their overall health. 
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Table 1: Baseline Characteristics of Study Patients† 
 Total* PB 
(N=14) 
BP 
(N=15) 
PB+MTM 
(N=16) 
BP+MTM 
(N=16) 
Gender, F 63.56% 50.0% 66.7% 68.8% 68.75% 
Age, years 56.35 50.3 57.8 60.3 57.0 
Education, % 
(N=51) 
     
Some High School 6.36% 0.0% 6.7% 12.5% 6.25% 
High School 8.13% 7.1% 6.7% 12.5% 12.5% 
Some College 26.4% 35.7% 20.0% 25.0% 25.0% 
Associate’s Degree 12.82% 0.0% 20.0% 18.8% 12.5% 
Bachelor’s Degree 18.05% 21.4% 13.3% 18.8% 18.7% 
Graduate Degree 10.36% 28.5% 6.7% 6.25% 0.0% 
Income, % (N=51)      
<$30,000 29.3% 21.4% 33.3% 43.8% 18.75% 
$30,000-$50,000 22.1% 7.1% 0.0% 31.3% 50.0% 
$50,000-$75,000 19.85% 21.4% 26.7% 18.8% 12.5% 
$75,000-$100,000 1.6% 0.0% 6.7% 0.0% 0.0% 
>$100,000 12.16% 35.7% 6.7% 6.25% 0.0% 
Average Number 
of Medications ± 
(SD) 
9.75 ± (3) 11 ± (1.3) 9 ± (2.5) 8 ± (2.7) 11 ± (2) 
BMI, kg/m2 ± (SD) 
(N=54) 
37.82 ± (4.17) 36.14 ± (4.28) 38.20 ± (2.50) 38.70 ± (3.30) 38.24 ± (4.12) 
HbA1c, % ± (SD) 8.63 ± (1.53) 8.7 ± (0.40) 8.5 ± (1.28) 8.8 ± (1.30) 8.5 ± (1.48) 
†No significant differences across groups 
*Total N=61, unless specified otherwise  
 
 
 
 
 
Table 2: Average Proportion of Days Covered Scores 
 PB (N=14)ab BP (N=15)a PB+MTM (N=16)c BP+MTM (N=16)bc 
Baseline 0.49 0.62 0.65 0.63 
3 months 0.63 0.85 0.77 0.87 
6 months 0.57 0.83 0.58 0.91 
9 months 0.50 0.91 0.71 0.92 
12 months 0.56 0.90 0.68 0.94 
aSignificant differences between groups (p=0.008) 
bSignificant differences between groups (p=0.023) 
cSignificant difference between groups at 6 months (p=0.041) 
*Except at baseline, adherence scores at all time points were significant with patients in the BP and BP+MTM groups having 
higher adherence compared to those in the PB and PB+MTM groups 
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Table 3: Average Pill Count Scores 
 PB (N=14)abefg BP (N=15)acg PB+MTM (N=16)cde BP+MTM (N=16)bdf 
Baseline 0.5480 0.6150 0.6789 0.6015 
3 months 0.6912 0.8517 0.7696 0.8672 
6 months 0.5568 0.8315 0.7051 0.7774 
9 months 0.5832 0.8800 0.7660 0.8911 
12 months 0.5924 0.8703 0.7734 0.9246 
aSignificant differences in adherence between groups (p=0.005) 
bSignificant differences between groups (p=0.002) 
cSignificant difference between groups at 6 months (p=0.012) 
dSignificant difference between groups at 12 months (p=0.031) 
eSignificant difference between groups at 12 months (p=0.001) 
fSignificant difference between groups at 6, 9, and 12 months (p<0.05) 
gSignificant difference between groups at 6, 9, and 12 months (p<0.05) 
 
 
 
Table 4: Comparison of HbA1c Scores Within and Across Groups 
HbA1c (%) ± (SD) PB Mean 
(N=14)cd 
BP Mean 
(N=15)§ 
PB+MTM Mean 
(N=16)c*§ 
BP+MTM Mean 
(N=16)d*§ 
Baseline 8.7 ± (0.40) 8.5 ± (1.28) 8.8 ± (1.30) 8.5 ± (1.48) 
6 months 8.5 ± (0.65) 7.6 ± (1.21) 7.3 ± (1.17) 7.2 ± (0.97) 
12 months 8.4 ± (0.81) 7.1 ± (0.92) 6.8 ± (1.62) 6.2 ± (0.53) 
*Significant change from baseline to 6 months (p<0.05) 
§Significant change from baseline to 12 months (p<0.05) 
cSignificant differences between groups (p<0.05)  
dSignificant differences between groups (p<0.05) 
 
 
 
Table 5: Comparison of BMI Scores Across Groups Over Time 
BMI (kg/m2) ± (SD)* PB Mean 
(N=14) 
BP Mean 
(N=14) 
PB+MTM Mean 
(N=14) 
BP+MTM Mean 
(N=13) 
Baseline 36.14 ± (4.28) 38.20 ± (2.50) 38.70 ± (3.30) 38.24 ± (4.12) 
6 months 36.81 ± (3.97) 37.90 ± (3.16) 37.91 ± (2.13) 37.6 ± (3.36) 
12 months 37.08 ± (3.45) 37.51 ± (3.24) 37.31 ± (2.27) 36.52 ± (2.68) 
*No statistically significant differences across groups  
 
 
 
Table 6: Comparison of SBP and DBP Scores Across Groups 
Visit PB Mean 
(N=14) 
BP Mean 
(N=15) 
PB+MTM Mean 
(N=16) 
BP+MTM Mean 
(N=16) 
SBP (mmHg) ± (SD)* 
Baseline 123.31 ± (12.28) 129.87 ± (11.0) 121.56 ± (9.62) 124.62 ± (8.73) 
6 months 126.18 ± (11.22) 104.40 ± (7.85) 126.79 ± (11.31) 107.40 ± (10.45) 
12 months 129.33 ± (7.45) 121.82 ± (5.24) 128.55 ± (9.27) 119.93 ± (7.48) 
DBP (mmHg) ± (SD)* 
Baseline 89.79 ± (8.28) 77.02 ± (4.18) 82.64 ± (5.78) 89.13 ± (7.24) 
6 months 72.91 ± (5.75) 75.15 ± (7.59) 74.00 ± (8.95) 65.62 ± (5.68) 
12 months 79.56 ± (3.43) 74.73 ± (9.00) 66.64 ± (3.81) 74.22 ± (10.36) 
n=17 patients were hypertensive at baseline 
*No statistically significant differences across groups  
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Appendix 1: CONSORT Flow 
 
 
 
 
Assessed for eligibility (n=394) 
Excluded (n=333) 
• Not meeting 
inclusion criteria 
(n=106) 
• Declined to 
participate (n=197) 
• Other reasons (n=30) 
Randomized (n=61) 
Allocated to Pill Bottle 
(PB) (n=14) 
• Received 
intervention 
(n=14) 
Allocated to Blister 
Pack (BP) (n=15) 
• Received 
intervention 
(n=15) 
Allocation 
Lost to follow-up 
because unable to 
reach (n=0) 
Follow-Up 
Analysis 
Analyzed (n=14) 
Lost to follow-up 
because unable to 
reach (n=0) 
Analyzed (n=15) 
Allocated to PB + MTM 
(n=16) 
• Received 
intervention 
(n=16) 
Allocated to BP + MTM 
(n=16) 
• Received 
intervention 
(n=16) 
Lost to follow-up 
because unable to 
reach (n=0) 
Analyzed (n=16) 
Lost to follow-up 
because unable to 
reach (n=0) 
Analyzed (n=16) 
